Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Deals  ·  Weekly Digest -04 July to 10 July
RyboDyn awarded USD 1.3 million department of war grant to advance novel antibody therapies for lung cancer

Weekly Digest – July 2026 Weekly Digest – July 2026 29 June 2026: Enhertu approved in the EU as the first tumor-agnostic HER2-targeted ADC for previously treated HER2 positive metastatic Solid tumors The European Union has approved Enhertu as the […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 04 July to 10 July
RyboDyn partners with U.S. Department of War to advance AI-discovered ADC therapies for Lung cancer

Weekly Digest – July 2026 Weekly Digest – July 2026 09 July 2026: RyboDyn partners with U.S department of war to advance AI-discovered ADC therapies for Lung cancer RyboDyn received a $1.3 million grant from the U.S. Department of War […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 27 June to 03 July 2026
Enhertu approved in the EU as the first tumor-agnostic HER2-targeted ADC for previously treated HER2 positive metastatic Solid tumors

Weekly Digest – July 2026 Weekly Digest – July 2026 29 June 2026: Enhertu approved in the EU as the first tumor-agnostic HER2-targeted ADC for previously treated HER2 positive metastatic Solid tumors The European Union has approved Enhertu as the […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 27 June to 03 July 2026
Datroway recommended for approval in the EU as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy

Weekly Digest – July 2026 Weekly Digest – July 2026 26 June 2026: Datroway recommended for approval in the EU as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy AstraZeneca and Daiichi Sankyo’s Datroway has […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 27 June to 03 July 2026
SYS6043 granted BTD in China for the treatment of platinum-resistant Ovarian cancer

Weekly Digest – July 2026 Weekly Digest – July 2026 02 July 2026: SYS6043 granted BTD in China for the treatment of platinum-resistant Ovarian cancer CSPC Pharmaceutical Group has received Breakthrough Therapy Designation from China’s NMPA for SYS6043, a B7-H3-targeted […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 27 June to 03 July 2026
FDA alignment to advance ProstACT Global phase 3 trial

Weekly Digest – July 2026 Weekly Digest – July 2026 02 July 2026: FDA alignment to advance ProstACT Global phase 3 trial Telix Pharmaceuticals has reached alignment with the U.S. FDA to advance the ProstACT Global phase 3 trial of […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 27 June to 03 July 2026
Glenmark advances phase 3 trial of Trastuzumab rezetecan in platinum-resistant Ovarian cancer

Weekly Digest – July 2026 Weekly Digest – July 2026 02 July 2026: Glenmark advances phase 3 trial of Trastuzumab rezetecan in platinum-resistant Ovarian cancer Glenmark has advanced the multi-country phase 3 clinical trial of SHR-A1811, a HER2-targeted antibody-drug conjugate, […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 27 June to 03 July 2026
CSPC initiates phase 3 trial of SYS-6010 in combination with Enlonstobart in resected stage II–IIIB NSCLC

Weekly Digest – July 2026 Weekly Digest – July 2026 30 June 2026: CSPC initiates phase 3 trial of SYS-6010 in combination with Enlonstobart in resected stage II–IIIB NSCLC CSPC Pharmaceutical Group has initiated the phase 3 SYS6010-015 trial in […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 20 June to 26 June 2026
Biokin Pharma secures first China approval for Iza-bren in Nasopharyngeal carcinoma

Weekly Digest – June 2026 Weekly Digest – June 2026 22 June 2026: SystImmune secures first China approval for Iza-bren in Nasopharyngeal carcinoma Biokin Pharma has received NMPA approval for Iza-bren for the treatment of recurrent or metastatic nasopharyngeal carcinoma […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 20 June to 26 June 2026
U.S. FDA approves Trodelvy for first-line treatment of metastatic TNBC

Weekly Digest – June 2026 Weekly Digest – June 2026 24 June 2026: U.S. FDA approves Trodelvy for first-line treatment of metastatic TNBC Gilead Sciences has received U.S. FDA approval for Trodelvy as a first-line treatment for adults with unresectable […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous91011121314151617Next ›Last »
Page 13 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id